Comparative Pharmacology
Head-to-head clinical analysis: NORCEPT E 1 35 28 versus NORETHIN 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORCEPT E 1 35 28 versus NORETHIN 1 35E 28.
NORCEPT-E 1/35 28 vs NORETHIN 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
Combination estrogen-progestin oral contraceptive. Ethinyl estradiol suppresses FSH and LH, preventing ovulation. Norethindrone alters cervical mucus and endometrial lining, inhibiting sperm penetration and implantation.
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
One tablet orally once daily for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 35 mcg, followed by 7 inert tablets).
None Documented
None Documented
Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days.
Norethindrone: terminal elimination half-life approximately 8-11 hours. Ethinyl estradiol: terminal elimination half-life approximately 10-20 hours (mean ~13 hours). Clinical context: Steady-state achieved within 5 days; once-daily dosing maintains therapeutic levels.
Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile.
Norethindrone is excreted primarily in urine as glucuronide and sulfate conjugates, with about 50-60% excreted renally; approximately 20-30% is excreted in feces via biliary elimination. Ethinyl estradiol is excreted in urine (40-60%) and feces (20-40%) after enterohepatic recirculation.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive